Showing results (151-160 of 161) with videos related to

Sort By:
Pageof 17
Cancers|August 14, 2025
Apalutamide Monotherapy in Metastatic Hormone-Sensitive Prostate Cancer: A Viable Alternative to First-Generation Anti-Androgen Agents to Avoid the Flare Phenomenon and an Effective Treatment for Achieving Early PSA ResponseGaetano Facchini, Andrea D'Arienzo, Antonella Nicastro, et al.
JAMA Oncology|August 12, 2021
Cetuximab Rechallenge Plus Avelumab in Pretreated Patients With RAS Wild-type Metastatic Colorectal Cancer: The Phase 2 Single-Arm Clinical CAVE TrialErika Martinelli, Giulia Martini, Vincenzo Famiglietti, et al.
Journal of Clinical Medicine|May 14, 2025
Cardio-Oncology Challenges in Elderly PatientsEster Topa, Eliana De Rosa, Alessandra Cuomo, et al.
Iscience|March 4, 2025
DNA-PK inhibition sustains the antitumor innate immune response in small cell lung cancerCaterina De Rosa, Floriana Morgillo, Luisa Amato, et al.
European Journal of Cancer (Oxford, England : 1990)|August 21, 2020
AXL is a predictor of poor survival and of resistance to anti-EGFR therapy in RAS wild-type metastatic colorectal cancerClaudia Cardone, Bernadette Blauensteiner, Veronica Moreno-Viedma, et al.
The Lancet. Oncology|May 31, 2022
Upfront FOLFOXIRI plus bevacizumab with or without atezolizumab in the treatment of patients with metastatic colorectal cancer (AtezoTRIBE): a multicentre, open-label, randomised, controlled, phase 2 trialCarlotta Antoniotti, Daniele Rossini, Filippo Pietrantonio, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|July 15, 2023
Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer: An early exploratory analysis of real-world dataMargherita Rimini, Lorenzo Fornaro, Sara Lonardi, et al.
European Journal of Cancer (Oxford, England : 1990)|July 16, 2025
Integrating tissue and liquid biopsy comprehensive genomic profiling to predict efficacy of anti-EGFR therapies in metastatic colorectal cancer: Findings from the CAPRI-2 GOIM studyDavide Ciardiello, Luca Boscolo Bielo, Stefania Napolitano, et al.
ESMO Open|March 4, 2017
Career opportunities and benefits for young oncologists in the European Society for Medical Oncology (ESMO)Gilberto Morgan, Matteo Lambertini, Hampig Raphael Kourie, et al.
Targeted Oncology|May 1, 2024
Durvalumab Plus Gemcitabine and Cisplatin Versus Gemcitabine and Cisplatin in Biliary Tract Cancer: a Real-World Retrospective, Multicenter StudyMargherita Rimini, Gianluca Masi, Sara Lonardi, et al.
Pageof 17